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Abstract: Mitochondrial diseases (MD) are a group of genetic and acquired disorders which present
significant diagnostic challenges. Here we report the disease characteristics of a large cohort of
pediatric MD patients (n = 95) with a definitive genetic diagnosis, giving special emphasis on clinical
muscle involvement, biochemical and histopathological features. Of the whole cohort, 51 patients
harbored mutations in nuclear DNA (nDNA) genes and 44 patients had mutations in mitochondrial
DNA (mtDNA) genes. The nDNA patients were more likely to have a reduction in muscle fiber
succinate dehydrogenase (SDH) stains and in SDH-positive blood vessels, while a higher frequency
of mtDNA patients had ragged red (RRF) and blue fibers. The presence of positive histopathological
features was associated with ophthalmoplegia, myopathic facies, weakness and exercise intolerance.
In 17 patients younger than two years of age, RRF and blue fibers were observed only in one case,
six cases presented cytochrome c oxidase (COX) reduction/COX-fibers, SDH reduction was observed
in five and all except one presented SDH-positive blood vessels. In conclusion, muscle involvement
was a frequent finding in our series of MD patients, especially in those harboring mutations in
mtDNA genes.
Keywords: mitochondrial diseases; myopathy; pediatric patients; biochemical markers; muscle
histopathology; next generation sequencing
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1. Introduction
Of all inherited metabolic diseases, mitochondrial diseases (MD) occur at the highest frequency
(incidence around 1/5000 births) [1]. The double genetic control of the oxidative phosphorylation
(OXPHOS) pathway (controlled by nuclear DNA (nDNA) and mitochondrial DNA (mtDNA)) means
that it is possible to inherit MD through either mode of inheritance [1]. Furthermore, the intricate
and fundamental metabolic pathways occurring in mitochondria leads to, amongst other problems, a
remarkable difficulty reaching an etiological diagnosis of MD [2]. Genotype-phenotype correlations
for MD are not well-established because mutations in the same gene can cause varied clinical
phenotypes (allelic heterogeneity) and similar clinical pictures can be caused by mutations in
different mitochondrial genes (locus heterogeneity) [1,3]. Furthermore, genetic disturbances in other
non-mitochondrial pathways may mimic MD or even cause a secondary mitochondrial dysfunction [3].
From a clinical point of view, there are classical and well-recognized mitochondrial syndromes
that have been extensively reported [1,4]. In these cohorts of patients, mutations either in nDNA or
mtDNA genes are the cause of the disease. In other cases, clinical pictures may be incomplete and
unspecific, especially at pediatric age, increasing diagnostic difficulties [1,4]. In most pediatric patients,
the clinical signs may be considered severe or even life-threatening, especially when MD appears early
in life. High-energy demanding tissues are affected first, with neuromuscular involvement being one
of the cardinal features of MD [5,6].
At present, a MD diagnosis can require extensive non-invasive and invasive tests including
clinical and biochemical studies, imaging, neurophysiology and muscle pathology assessment, and,
as a final step, definitive molecular genetic confirmation [4]. A biochemical analysis for MD includes
the measurement of lactate, pyruvate, amino acids, FGF-21, and GDF-15 in blood and organic acids
in urine, as well as routine parameters such as creatine kinase (CPK) to assess muscle involvement.
However, even when used in combination, neither high specificity nor high sensitivity is expected [4,7].
Cerebrospinal fluid analysis of lactate and other biomarkers may improve the diagnostic yield of blood
tests [8]. Other biomarkers, such as methylglutaconic, thymidine, or coenzyme Q10, may provide
further insights to elucidate furthering the aetiology of MD [7]. A muscle biopsy may be required to
complete the diagnostic process since various typical features of the muscle can be detected even in
the absence of clinical muscle involvement, and it may be of paramount importance in the diagnostic
workflow [1,4].
Although the advent of next-generation sequencing techniques (NGS) is changing the diagnostic
paradigm [9–18], a remarkable percentage of patients (around 50% in most series) remain undiagnosed,
or they are ultimately diagnosed with other non-mitochondrial conditions. NGS has facilitated
diagnosis, and several recently reported patient series associated more than 290 genes as causative
of MD [19]. Different genetic approaches have been applied, including targeted mitochondrial gene
panels, whole exome (WES) and whole genome sequencing (WGS) and, recently, the combined genetic
analysis of both mtDNA and nDNA [20,21]. As a result, not only is diagnostic efficacy enhanced,
but new pathomechanisms are being unraveled, and unexpected findings are being recognized [17].
Taking the above details together, our overall goal is to report the disease characteristics of a large
cohort of pediatric MD patients with a definitive molecular diagnosis, with a special emphasis on
clinical muscle involvement and biochemical, histopathological, and genetic features.
2. Material and Methods
2.1. Patients
Over the last 25 years, we have recruited a cohort of 108 pediatric patients with MD who have
visited Hospital Sant Joan de Déu. This study was approved by the local Ethics Committee (protocol
number PIC-149-17) and performed in accordance with the Declaration of Helsinki. All participants
signed an informed consent. Of this initial cohort of patients, 13 were excluded from the study because
no clinical, biochemical, or histological data were available in the clinical records. This was because
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they were patients who visited only once and follow-up was not possible, or because they were
diagnosed after an acute presentation with a fatal outcome. Large family cohorts (for example the
MELAS (mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) patients previously
reported by our group [22]) were not included in the study. Thus, a final cohort of 95 patients were
included (age range, between 1 day and 16 years, average age of 4.0 years, standard error of the mean
(SEM) = 0.45; sex distribution 40 females and 55 males). The main clinical details, and biochemical,
histopathological, and molecular data are reported in Table S1.
2.2. Methods
2.2.1. Patient Recruitment
MD patients are usually diagnosed with a combination of clinical, biochemical, and
histopathological data, when the genetic bases of the disease are elusive [1]. In this work we recruited
MD patients only when genetic diagnosis was positive, and they were further classified depending on
the origin of mutation (nDNA (n = 59) or mtDNA (n = 44)). This classification is relevant since the
clinical phenotype (including muscular involvement), the way of inheritance, the familial antecedents
and other features are different in mtDNA and nDNA patient groups. For the patient selection,
we included genes with a primary role specific to OXPHOS biogenesis and genes with a secondary
impact on OXPHOS biogenesis as well as other cellular functions, as reported by Frazier et al. [19].
The biological functions of these genes include: (1) OXPHOS subunits, assembly factors and electron
carriers; (2) mtDNA maintenance; (3) mtDNA expression; (4) enzyme cofactors; (5) mitochondrial
homeostasis and quality control; and (6) general energy metabolism [19]. In Table S1, the different
molecular mechanisms associated with the mutated genes are stated.
2.2.2. Clinical Data
Data collected from medical records included age of presentation, gender, survival (age of death)
and specific muscular signs and symptoms such as ophthalmoplegia, myopathic facies, exercise
intolerance, weakness, rhabdomyolysis and myopathic electromyography (EMG). Data were available
from 78 patients.
2.2.3. Samples
Blood, urine, and when indicated, muscle or other tissue biopsies were collected for diagnostic
purposes and stored in the Hospital Sant Joan de Déu Biobank. DNA from blood and muscle samples
was isolated using standard procedures. Samples were taken in accordance with the 2013 revised
Helsinki Declaration of 1964. Parental informed consent forms were obtained in all cases. The ethical
committee of Sant Joan de Déu Hospital approved the study.
2.2.4. Biochemical Analysis
Blood lactate, pyruvate, amino acids (alanine), FGF-21/GDF-15, CPK and urine organic acids
(lactate and Krebs cycle metabolites) were analyzed as previously reported [7,23] in 89 patients.
Hyperlactacidemia was only considered when 2 or more blood lactate levels were documented (the
same criterion was used for pyruvate and alanine) [1].
2.2.5. Histopathological Analysis
Sixty muscle biopsies were studied (average age at biopsy was 5.86 years; SEM = 0.78). All muscle
biopsies were analyzed by an experienced neuropathologist. Each muscle specimen was collected
from quadriceps and processed and stained according to standard protocols with modified Gomori
trichrome, succinate dehydrogenase (SDH), cytochrome c oxidase (COX) and oil-red O stain for
lipids [4]. The following muscular pathological features were recorded: ragged red fibers (RRF), fibers
with increased SDH staining (blue fibers), COX negative fibers (COX-), COX reduction, SDH reduction
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and SDH-positive blood vessels. To compare histopathological features of MD infant patients (younger
than 2 years old), we assessed the presence of COX-, RRF/blue fibers, SDH reduction, SDH-positive
blood vessels and lipid increase (1) in 17 cases selected from the whole cohort of patients. As a control
group, we studied 12 patients with different congenital myopathies: nemalinic (n = 5), myotubular
(n = 2), central core (n = 1), merosin-deficient congenital muscular dystrophy (MDC1A) (n = 3) and
congenital myotonic dystrophy type 1 (DM1) (n = 1).
2.2.6. Genetic Analysis
Because the patients were studied over the past 25 years, different approaches were applied for
genetic diagnosis. The mtDNA mutations were studied by specific procedures, including SANGER
sequencing, Southern-blot, and real-time polymerase chain reaction (PCR), as previously reported [22].
Depending on the suspected causative gene, nuclear DNA was analyzed either by SANGER sequencing,
or, over the past 4 years, by NGS, with customized [24] or commercial panels (TruSight One
Sequencing Panel, Illumina (San Diego, CA, USA)) using MiSeq and NextSeq500 sequencers (Illumina).
Whole exome sequencing was only performed in selected cases. To test the nuclear mutations detected,
SANGER sequencing was done in all cases. Progenitor studies, in-silico analysis or functional-cellular
studies were carried out to evaluate the inheritance model and to confirm the pathogenicity of genetic
variants, when required.
2.2.7. Statistical Analysis
We categorized the clinical, biochemical and histological data as normal or impaired (see Table S1).
Statistical associations among the different categorical variables were studied with the chi-square test
using the SPSS 20.0 program (IBM, Armonk, NY, USA).
3. Results
Muscular clinical signs, and biochemical and histopathological data for the whole patient cohort
and for the mtDNA and nDNA subgroups are presented in Table 1 and Figure 1. A total of 51 patients
harbored mutations in nDNA and 44 patients had mutations in mtDNA. Age was significantly lower
in the nDNA group (average: 2.7 years, SEM 0.45) when compared with the mtDNA group (5.4 years,
SEM 0.76) (Mann-Whitney U-test p < 0.0001). A higher frequency of nDNA patients had muscle SDH
reduction and SDH-positive vessels, while a higher frequency of mtDNA patients had RRF, blue fibers,
and nearly significative for ophthalmoplegia and exercise intolerance (Table 1, Figure 1).
We classified the 95 patients according to their clinical features (presence or absence of myopathy)
and to histopathological features (RRF, blue or COX-fibers, positive or negative) (Table 2). As expected,
the presence of muscular involvement was associated with positive RRF, blue and COX-fibers.
Moreover, positive histopathological features were associated with ophthalmoplegia, myopathic
facies, weakness and exercise intolerance. No associations were observed in these two groups for other
variables, including the biochemical markers.
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Table 1. Clinical, biochemical, and histopathological data in the whole cohort of patients classified as
having nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) mutations. Results are expressed as
the percentage of cases with impaired biomarkers (elevated concentration above normal cut-off value),
percentage of patients presenting with myopathic features, and percentage of muscle biopsies with
positive features. Chi-square was calculated to look for associations between the different variables
listed in the left column (categorized as presence or absence) and whether the mutation was in the
nDNA or mtDNA. nDNA patients showed a higher frequency of succinate dehydrogenase (SDH)
reduction and SDH-positive vessels, while mtDNA patients showed a higher frequency of ragged red
(RRF) and blue fibers.
Percentage (%) Total Group(n = 103)
nDNA Patients
(n = 59)
mtDNA Patients
(n = 44) Chi-Square
Sex (M/F) 58.3/41.7 57.6/42.4 59.1/40.9 n.s.
Exitus 41.7 40.6 44.4 n.s.
Survival (years) 6.7 11.9 n.s.
Biomarkers
Lactate 79.8 81.5 77.5 n.s
Pyruvate 69.1 76.1 60.0 n.s.
Alanine 64.9 61.1 70.0 n.s
Organic acids 35.3 34.0 37.5 n.s
GDF-15/FGF-21 51.4 48.0 60.0 n.s
Myopathy
CPK 28.3 37.1 16.0 n.s.
Ophthalmoplegia 23.4 15.9 33.3 n.s.
Myopathic facies 20.8 16.3 26.5 n.s.
Exercise intolerance 25.3 16.7 36.4 n.s.
Weakness 26.0 22.7 30.3 n.s.
Rhabdomyolysis 3.9 4.7 2.9 n.s.
EMG (myopathic) 19.9 18.5 23.5 n.s. *
Histopathology
RRF 32.8 18.2 50.0 6.959 (p = 0.008)
Blue fibers 36.0 20.0 60.0 8.333 (p = 0.004)
COX negative 39.6 41.4 36.8 n.s.
COX reduction 50.0 51.7 47.4 n.s.
SDH reduction 22.4 34.5 5.0 5.910 (p = 0.015)
Positive SDH (Vessels) 65.8 85.7 41.2 8.828 (p = 0.004)
n.s. = non-significative; * 33.3% of nDNA and 29.4% of mtDNA patients presented a normal Electromyography
(EMG) while 48.2% and 47.1% showed neuropathic features; M, male; F, female; CPK, creatine phosphate kinase;
RRF, ragged red; SDH, succinate dehydrogenase; COX, cytochrome c oxidase.
Table 2. Patients were classified as having or not having positive histopathological features (RRF,
blue or cytochrome c oxidase negative (COX-) fibers; positive/negative) and muscular involvement
(ophthalmoplegia, myopathic facies, exercise intolerance, weakness, high creatine kinase (CPK) values
or myopathic electromyography (EMG); yes/no). Significantly positive associations among the different
variables in these groups of patients are stated. Results are expressed as % of patients with the four
myopathic and the three histopathological features listed in the left column.
Histopathology Chi-Square
Positive Negative
Myopathy
Ophthalmoplegia 44.0 8.3 7.991 (p = 0.005)
Myopathic facies 33.3 8.3 4.547 (p = 0.033)
Exercise intolerance 45.8 4.5 10.148 (p = 0.001)
Weakness 48.0 0 14.720 (p < 0.0001)
Muscular Involvement Chi-Square
Yes No
Histopathology
RRF 63.6 13.8 13.609 (p < 0.0001)
Blue fibers 65.0 18.5 10.505 (p = 0.001)
COX negative 63.2 16.0 10.375 (p = 0.001)
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Figure 1. Percentage of impaired biomarkers (A), muscular involvement (B) and positive 
histopathological features (C) in nDNA (black bars) and mtDNA (grey bars) patients. Whiskers 
indicate significant differences (chi-square test) between nDNA and mtDNA groups. nDNA patients 
showed significantly higher frequency of SDH reduction and SDH-positive vessels, while mtDNA 
patients shower a higher frequency of RRF and blue fibers, and near significative for ophthalmoplegia 
and exercise intolerance. nDNA, nuclear DNA; mtDNA, mitochondrial DNA; CPK, creatine 
phosphate kinase; EMG, myopathic electromyography; RRF, ragged red; SDH, succinate 
dehydrogenase; COX, cytochrome c oxidase. 
Muscle biopsies were concomitantly analyzed in 15 cases for serum GDF-15 and FGF-21 levels. 
There were 6 cases with normal FGF-21/GDF-15, and neither RRF nor blue fibers were detected (there 
were only two COX-fiber cases). In the 9 cases showing high FGF-21/GDF-15 values, RRF were 
observed in four cases, blue fibers in five cases and COX-fibers in seven cases. 
In the whole cohort of patients, the most frequent histopathological finding was SDH-positive 
vessels, followed by COX reduction/COX-fibers (Table 1). In the 17 patients that were less than 2 
years of age, RRF and blue fibers were observed only in one case (mutations in TK2), six cases 
presented COX reduction/COX-fibers (mutations in AGK, PUS1, KARS, SUCLA2, MT-ATP6 and TK2) 
and SDH reduction was found in five patients (mutations in PUS1, ECHS1, KARS, MT-ATP6 and 
COX7). All of them, with one exception, presented SDH-positive blood vessels. Lipids were increased 
in 9 out of 10 biopsies analyzed. In the 12 cases with congenital myopathies, no RRF/blue fibers were 
observed and SDH reduction was detected only in one case (DM1). We observed COX reduction in 
four cases, corresponding to MDC1A (two cases), DM1 (one case) and nemaline myopathy (one case). 
SDH-positive blood vessels were detected in all of these 12 cases. No increased lipids were observed 
in any of them. In Figure 2, the main histopathological features in selected infants with MD and non-
mitochondrial congenital myopathies are shown. 
Figure 1. Percentage of impaired biomarkers (A), muscular involvement (B) and positive
histopathological features (C) in nDNA (black bars) and mtDNA (grey bars) patients. Whiskers indicate
significant differences (chi-square test) between nDNA and mtDNA groups. nDNA patients showed
significantly higher frequency of SDH reduction and SDH-positive vessels, while mtDNA patients
shower a higher frequency of RRF and blue fibers, and near significative for ophthalmoplegia and
exercise intolerance. nDNA, nuclear DNA; mtDNA, mitochondrial DNA; CPK, creatine phosphate
kinase; EMG, myopathic electromyography; RRF, ragged red; SDH, succinate dehydrogenase; COX,
cytochrome c oxidase.
Muscle biopsies were concomitantly analyzed in 15 cases for serum GDF-15 and FGF-21 levels.
There were 6 cases with r al FGF-21/GDF-15, a d neither RRF nor lue fibers were detected
(ther were only two COX-fiber cases). In the 9 ca e showing high FGF-21/GDF-15 values, RRF w re
observed in four case , blue fibers in five cases and COX-fiber s.
In the whole cohort of patients, the most frequent hist ical finding was SDH-positive
vess l , foll wed by COX reduction/ -fibers (Table 1). In the 17 patien s that were less than
2 years of age, RRF an bl e fi ers ere ser ed nly in one case (mutations in TK2), six cases
presented COX reduction/COX-fibers (mutations in AGK, P S1, KARS, SUCLA2, MT-ATP6 and TK2)
and SDH reduction was found in five patients (mutations in PUS1, ECHS1, KARS, MT-ATP6 and
COX7). All of them, with one exception, presented SDH-positive blood vessels. Lipids were increased
in 9 out of 10 biopsies analyzed. In the 12 cases with congenital myopathies, no RRF/blue fibers
were observed and SDH reduction was detected only in one case (DM1). We observed COX reduction
in four cases, corresponding to MDC1A (two cases), DM1 (one case) and nemaline myopathy (one
case). SDH-positive blood vessels were detected in all of these 12 cases. No increased lipids were
observed in any of them. In Figure 2, the main histopathological features in selected infants with MD
and non-mitochondrial congenital myopathies are shown.
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Figure 2. Main histopathological features (quadriceps muscle) of 5 infants with mitochondrial disease 
(MD) and other congenital myopathies. (1) Patient with AGK mutations (3 days old); (1A): Total 
absence of COX (arrows). (1B): Normal stain of SDH (arrows). (1C): SDH-positive vessels (star). (1D): 
Modified Gomori trichrome: No RRF (arrow marks a normal fiber). (2) Patient with SUCLA2 
mutations (6 months old); (2A): Isolated COX negative fibers (arrows). (2B): Mild reduction of SDH 
(arrows). (2C): SDH-positive vessels (star). (2D) Modified Gomori trichrome: occasional 
subsarcolemal mitochondrial proliferation (arrows). (3) Patient with MT-ATP6 mutations (1 month 
old); (3A): COX: Muscular fibers with a normal pattern showing the highest intensity of stain in type 
I fibers, and pale and intermediate intensity in type II fibers (arrow mark a type I muscular fiber). 
(3B): Muscular fibers with normal SDH stain. (3C): SDH-positive vessels (star). (3D): Muscular fibers 
with normal pattern and no RRF with modified Gomori trichrome stain. (4) Patient with LAMA2 
mutations (6 months old) (4A): Isolated fibers with COX reduction consistent with pre-necrotic fibers 
(arrows). (4B): Isolated fibers with SDH reduction (arrows). (4C): SDH-positive vessels (star). (4D): 
Modified Gomori trichrome; marked increase of endomysial tissue (star) consistent with dystrophic 
pattern, no RRF. (5) Patient with miotubularin mutation (1 month old). (5A): No COX negativefibers 
(arrows). (5B): No reduction of SDH (arrows). (5C): SDH-positive vessels (star). (5D): Modified 
Gomori trichrome. Large central nuclei in several fibers (arrows). No RRF. 
The number of genetic diagnoses (nDNA) has significantly increased within the last 4 years due 
to the application of NGS techniques. In the 2015–2018 period, from the whole cohort of patients, a 
total of 26 cases harboring nDNA mutations were solved by NGS. There are still some unsolved cases 
(Table S1), corresponding to patients with mtDNA depletions or multiple deletions where the 
molecular bases are under investigation (nDNA). 
4. Discussion 
Here, we report one of the largest cohorts of pediatric patients with a molecular diagnosis of a 
MD. While most of the previous works have reported on the diagnostic yield of NGS techniques in 
MD patients [9–21], in this study we focused our attention on muscular features of pediatric MD 
patients with a definitive molecular diagnosis, as the ultimate biomarker (Table S1). 
Regarding blood and urine MD biochemical markers, no differences were observed when 
comparing nDNA and mtDNA patient cohorts. The most frequent cause of an impaired result was 
lactate and pyruvate, but they have a lack of specificity since a wide variety of genetic and 
environmental conditions can lead to increased lactate values [7]. GDF-15 and FGF-21 have been 
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The number of genetic diagnoses (nDNA) has significantly increased within the last 4 years due
to the application of NGS techniques. In the 2015–2018 period, from the whole cohort of patients,
a total of 26 cases harboring nDNA mutations were solved by NGS. There are still some unsolved
cases (Table S1), corresponding to patients with mtDNA depletions or multiple deletions where the
molecular bases are under investigation (nDNA).
4. Discussion
Here, we report one of the largest cohorts of pediatric patients with a molecular diagnosis of a
MD. While most of the previous works have reported on the diagnostic yield of NGS techniques in MD
patients [9–21], in this study we focused our attention on muscular features of pediatric MD patients
with a definitive molecular diagnosis, as the ultimate biomarker (Table S1).
Regarding blood and urine MD biochemical markers, no differences were observed when
comparing nDNA and mtDNA patient cohorts. The most frequent cause of an impaired result
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was lactate and pyruvate, but they have a lack of specificity since a wide variety of genetic and
environmental conditions can lead to increased lactate values [7]. GDF-15 and FGF-21 have been
reported as promising biomarkers that increase diagnostic specificity, especially when muscular
involvement is observed [23,25]. No differences were observed in these biomarkers when comparing
clinical muscular features, but data were more predictive when considered together with histological
features. Although no statistical analysis could be done due to the limited size of the series (only
data from 15 patients with both FGF-21/GDF-15 analysis and muscle biopsy studies were available),
a remarkable relationship between increased concentrations of these biomarkers and the presence of
RRF, and blue/COX-fibers indicating muscle affectation was observed.
From a clinical point of view, the percentage of mtDNA vs. nDNA mutations in our series
of patients was relatively balanced, although it is well known that mtDNA defects are much more
frequent in adults than nDNA ones [1,19,26]. This finding is probably due to a biased selection in our
patient cohort, as over the past few decades it has become easier to identify mutations in mtDNA
than in nDNA. Muscular involvement was a prominent feature in the studied patients, which is
similar to other reported series [1]. The higher frequency of muscular signs in the mtDNA group may
be explained by the older age of this group when compared with nDNA patients, some of whom
experienced disease onset during the newborn period or infancy with a fatal outcome. This fact could
also explain the lack of differences in survival between these two patient groups, since some mtDNA
patients were diagnosed several years ago, while most of the nDNA were recently identified, having a
shorter follow-up period.
Histological features in MD patients have been extensively reported [4]. New technological
developments have been recently published that are relevant to MD diagnosis, especially methods
related to a sensitive quadruple immunofluorescent technique which enables the accurate quantification
of key OXPHOS protein abundance and porin in individual myofibers [27]. Here, we evaluated only the
classical biomarkers, since the cohort was recruited over the last 25 years and no immunofluorescence
studies were available for older patients. COX/SDH histochemistry is the standard method used to
assess mitochondrial respiratory chain function in muscle cryosections. The activities of the partially
mtDNA-encoded complex IV (COX) and the fully nuclear-encoded complex II (SDH) [28] are seen
as a mosaic reduction or loss of COX activity with preserved SDH activity (blue fibers), indicative of
an underlying mtDNA-related abnormality. RRF reflects mitochondrial replication to compensate for
energy failure [28]. Our mtDNA patients showed a higher percentage of alterations in RRF and blue
fibers when compared with the nDNA group. Conversely, SDH staining alterations were higher in the
nDNA group of patients, especially with regards to SDH-positive vessels. In any case, there was a
trend of gradually increasing proportions of patients with mitochondrial histopathological features as
their age increased [26,28].
Pathological features in infants were studied; however, it is difficult to demonstrate major
alterations in muscle for this group, and the lack of RRF/blue fibers in children below the age of 5 years
makes a challenging diagnosis [26,28]. In our infant cohort, only one patient with aTK2 mutation
showed RRF/blue fibers, confirming these previous observations. The most frequent alteration found
in this cohort was COX-/COX reduction and SDH-positive blood vessels. Regarding COX studies,
it has been proposed that >2% COX-fibers in children may be indicative of MD [4]. In non-mitochondrial
myopathies in infants, only COX reduction (but no COX-fibers) was detected in four cases.
The presence of necrotic fibers (MDC1A) and nemaline rods, the latter causing a disrupted sarcomere
structure, could explain these findings. SDH reduction was observed only in the MD group, suggesting
that it might have a good specificity as a biomarker for MD diagnosis in infants, but no high sensitivity
(only 5 MD cases out of 17 presented this pathological feature). SDH-positive vessels were frequently
detected both in MD and non-MD patients (Figure 2), and it should be considered an unspecific finding,
at least in infants. An interesting finding was the higher presence of increased lipids in MD infants
compared to non-MD patients. Although this feature cannot be considered specific of MD (other lipid
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storage myopathies can present it in greater amount than MD), it could be an additional biomarker for
MD pathological diagnosis in infants [4,29].
Despite the increasing use of NGS and other omics approaches for unraveling novel mitochondrial
genes, current clinical practice for investigating MD essentially involves a multipronged approach
that includes clinical assessment, metabolic screening, imaging, and pathological, biochemical and
functional testing to guide molecular genetic analysis [4]; the latter should be considered as the unique
real biomarker for diagnosis of MD. Recently, Morava criteria were revisited, and it was demonstrated
to be a useful tool for facilitating the diagnostic workflow for MD [1]. In fact, there is still a notable
percentage of patients whose diagnosis is missing. Our results support, as in other reports, that NGS
techniques have substantially improved the diagnostic yield, especially for nDNA mutations, but
thorough clinical/phenotypical investigation is still required.
Present and future directions: The application of NGS techniques in recent years has remarkably
improved the diagnostic yield in MD. In this work, we report on our retrospective experience in the
diagnosis of MD pediatric patients by applying classical diagnostic approaches. However, since NGS
techniques are changing the diagnostic paradigm in genetic diseases in general, revisiting the diagnostic
protocols seems necessary. At present, non-invasive approaches are mandatory in the first-line
diagnosis of MD. A deep clinical investigation together with imaging and other complementary
test support, metabolic testing (in blood and urine) and DNA collection for NGS analysis is advisable,
avoiding invasive procedures. Depending on the results after this first line diagnosis, invasive
approaches may be considered as a second-step, such as investigations in muscle/skin biopsies to
interrogate mitochondrial function. This should be recommended only in cases with uncertain clinical
and molecular associations (new phenotypes, new mutations of uncertain significance, and especially
when new genes are candidates as a cause of MD). These kinds of approaches are supported by reputed
authors in the field [1], but in all likelihood in near-future, the NGS molecular diagnosis will be so
effective that it will be able to replace some of the diagnostic practices that are carried out today.
5. Conclusions
In conclusion, we report on the disease characteristics of a large series of pediatric MD patients,
where muscular involvement both at clinical and histopathological levels was prominent, especially
in those harboring mutations in mtDNA genes. The fast technological changes experienced in
recent years regarding NGS strongly advise to revisit the current diagnostic protocols in clinical
and laboratory settings.
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